Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression

Proteomics - Clinical Applications

Volumn 7, Issue 9-10, 2013, Pages 677-689

  Nyalwidhe, Julius O ^a   Betesh, Lucy R ^b   Powers, Thomas W ^c   Jones, E Ellen ^c   White, Krista Y ^a   Burch, Tanya C ^a   Brooks, Jasmin ^c   Watson, Megan T ^a   Lance, Raymond S ^a   Troyer, Dean A ^a   Semmes, O John ^a   Mehta, Anand ^b   Drake, Richard R ^c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Expressed prostatic secretion; Glycomics; N linked glycosylation; Prostate cancer; Urine exosome

Indexed keywords

GLYCAN; GLYCOPROTEIN; N ACETYLGLUCOSAMINE; POLYSACCHARIDE;

ARTICLE; CANCER GROWTH; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EXOSOME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SECRETION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; STRUCTURE ANALYSIS; CANCER GRADING; CHEMISTRY; DISEASE COURSE; GLYCOBIOLOGY; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SECRETION (PROCESS);

TETRA;

ACETYLGLUCOSAMINE; DISEASE PROGRESSION; GLYCOMICS; GLYCOPROTEINS; HUMANS; MALE; NEOPLASM GRADING; POLYSACCHARIDES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84885915953     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200134     Document Type: Article

References (57)

1. Leach, R., Thompson, I. M., The dilemma of prostate-specific antigen testing. Arch. Intern. Med. 2012, 172, 835-836.
2. Sokoll, L. J., Sanda, M. G., Feng, Z., Kagan, J. et al., A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2] proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 1193-1200.
3. Chou, R., Croswell, J. M., Dana, T., Bougatsos, C. et al., Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2011, 155, 762-771.
4. Chung, B. I., Tarin, T. V., Ferrari, M., Brooks, J. D., Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival. Urol. Oncol. 2011, 29, 314-318.
5. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D. et al., Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J. Clin. Oncol. 1998, 16, 3094-3100.
6. Abate-Shen, C., Shen, M. M., Molecular genetics of prostate cancer. Genes Dev. 2000, 14, 2410-2434.
7. Boyd, L. K., Mao, X., Lu, Y. J., The complexity of prostate cancer: genomic alterations and heterogeneity. Nat. Rev. Urol. 2012, 9, 652-664.
8. Iczkowski, K. A., Lucia, M. S., Current perspectives on Gleason grading of prostate cancer. Curr. Urol. Rep. 2011, 12, 216-222.
9. Ploussard, G., de la Taille, A., Urine biomarkers in prostate cancer. Nat. Rev. Urol. 2010, 7, 101-109.
10. Klotz, L., Active surveillance for prostate cancer: trials and tribulations. World J. Urol. 2008, 26, 437-442.
11. Salagierski, M., Schalken, J. A., Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J. Urol. 2012, 187, 795-801.
12. Drake, R. R., Elschenbroich, S., Lopez-Perez, O., Kim, Y. et al., In-depth proteomic analyses of direct expressed prostatic secretions. J. Proteome Res. 2010, 9, 2109-2116.
13. Principe, S., Kim, Y., Fontana, S., Ignatchenko, V. et al., Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J. Proteome Res. 2012, 11, 2386-2396.
14. Kim, Y., Ignatchenko, V., Yao, C. Q., Kalatskaya, I. et al., Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol. Cell. Proteomics 2012, 11, 1870-1884.
15. Drake, R. R., White, K. Y., Fuller, T. W., Igwe, E. et al., Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J. Proteomics 2009, 72, 907-917.
16. Peracaula, R., Tabares, G., Royle, L., Harvey, D. J. et al., Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003, 13, 457-70.
17. Prakash, S., Robbins, P. W., Glycotyping of prostate specific antigen. Glycobiology 2000, 10, 173-176.
18. Okada, T., Sato, Y., Kobayashi, N., Sumida, K. et al., Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. Biochim. Biophys. Acta 2001, 1525, 149-160.
19. Mattsson, J. M., Valmu, L., Laakkonen, P., Stenman, U. H., Koistinen, H., Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate 2008, 68, 945-954.
20. Tabares, G., Jung, K., Reiche, J., Stephan, C. et al., Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and Western blotting of immunopurified samples. Clin. Biochem. 2007, 40, 343-350.
21. Tajiri, M., Ohyama, C., Wada, Y., Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. Glycobiology 2008, 18, 2-8.
22. White, K. Y., Rodemich, L., Nyalwidhe, J. O., Comunale, M. A. et al., Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J. Proteomic Res. 2009, 8, 620-630.
23. Arienti, G., Carlini, E., Polci, A., Cosmi, E. V., Palmerini, C. A., Fatty acid pattern of human prostasome lipid. Arch. Biochem. Biophys. 1998, 358, 391-395.
24. Ronquist, G. K., Larsson, A., Stavreus-Evers, A., Ronquist, G., Prostasomes are heterogeneous regarding size and appearance but affiliated to one DNA-containing exosome family. Prostate 2012, 72, 1736-1745.
25. Block, T. M., Comunale, M. A., Lowman, M., Steel, L. F. et al., Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc. Natl. Acad. Sci. USA 2005, 102, 779-784.
26. Mehta, A., Carrouee, S., Conyers, B., Jordan, R. et al., Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 2001, 33, 1488-1495.
27. Guile, G. R., Rudd, P. M., Wing, D. R., Prime, S. B. et al., A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal. Biochem. 1996, 240, 210-226.
28. Comunale, M. A., Wang, J., Hafner, J., Krakover, L. et al., Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J. Proteome Res. 2009, 8, 595-602.
29. Mechref, Y., Kang, P., Novotny, M. V., Solid-phase permethylation for glycomic analysis. Methods Mol. Biol. 2009, 534, 53-64.
30. Kawinski, E., Levine, E., Chadha, K., Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids. Prostate 2002, 50, 145-153.
31. Sandra, K., Devreese, B., Van Beeumen, J., Stals, I. et al., The Q-Trap mass spectrometer, a novel tool in the study of protein glycosylation. J. Am. Soc. Mass Spectrom. 2004, 15, 413-423.
32. Wuhrer, M., Catalina, M. I., Deelder, A. M., Hokke, C. H., Glycoproteomics based on tandem mass spectrometry of glycopeptides. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 849, 115-128.
33. Domon, B., Costello, C. E., A systematic nomenclature for carbohydrate fragmentations in FABMS/MS spectra of glycoconjugates. Glycoconj. J. 1988, 54, 397-409.
34. Apte, A, Meitei, N. S., Bioinformatics in glycomics: glycan characterization with mass spectrometric data using SimGlycan. Methods Mol. Biol. 2010, 600, 269-281.
35. Scott, N. E., Parker, B. L., Connolly, A. M., Paulech, J. et al., Simultaneous glycan-peptide characterization using hydrophilic interaction chromatography and parallel fragmentation by CID, HCD and ETD-MS applied to the N-linked glycoproteome of Campylobacter jejuni. Mol. Cell. Proteomics 2011, 10, M000031MCP201.
36. Saba, J., Dutta, S., Hemenway, E., Viner, R., Increasing the productivity of glycopeptides analysis by using higher-energy collision dissociation-accurate mass-product-dependent electron transfer dissociation. Int. J. Proteomics 2012, 2012, 560391.
37. Huddleston, M. J., Bean, M. F., Carr, S. A., Collisional fragmentation of glycopeptides by electrospray ionization LC/MS and LC/MS/MS: methods for selective detection of glycopeptides in protein digests. Anal. Chem. 1993, 65, 877-884.
38. Raimondo, F., Morosi, L., Chinello, C., Magni, F., Pitto, M., Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics 2011, 11, 709-720.
39. Tavoosidana, G., Ronquist, G., Darmanis, S., Yan, J. et al., Multiple recognition assay reveals prostatsomes as promising plasma biomarkers for prostate cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 8809-8814.
40. Vlassov, A., Magdaleno, S., Setterquist, R., Conrad, R., Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 2012, 1820, 940-948.
41. Duijvesz, D., Luider, T., Bangma, C. H., Jenster, G., Exosomes as biomarker treasure chests for prostate cancer. Eur. Urol. 2011, 59, 823-831.
42. Marleau, A. M., Chen, C. S., Joyce, J. A., Tullis, R. H., Exosome removal as a therapeutic adjuvant in cancer. J. Transl. Med. 2012, 10, 134.
43. Alvarez, M., Khosroheidari, M., Ravi, R., DiStefano, K., Comparison of protein, microRNA and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012, 9, 1024-1032.
44. Nilsson, J., Skog, J., Nordstrand, A., Baranov, V. et al., Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 2009, 100, 1603-1607.
45. Principe, S., Jones, E. E., Kim, Y., Sinha, A. et al., In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics 2013, 13, 1667-1671.
46. Saldova, R., Fan, Y., Fitzpatrick, J. M., Watson, R. W. et al., Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011, 21, 195-205.
47. Abbott, K. L., Aoki, K., Lim, J. M., Porterfield, M. et al., Targeted glycoproteomic identification of biomarkers for human breast carcinoma. J. Proteome Res. 2008, 7, 1470-1480.
48. Guo, H., Nairn, A., dela Rosa, M., Nagy, T. et al., Transcriptional regulation of the protocadherin β cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching. J. Biol. Chem. 2012, 287, 24941-24954.
49. Lange, T., Ullrich, S., Müller, I., Nentwich, M. F. et al., Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1, 6)-branched oligosaccharides as a marker of tumor progression. Clin. Cancer Res. 2012, 18, 1364-1373.
50. Takahashi, M, Kuroki, Y, Ohtsubo, K, Taniguchi, N., Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr. Res. 2009, 344, 1387-1390.
51. Miwa, H. E., Song, Y., Alvarez, R., Cummings, R. D., Stanley, P., The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj. J. 2012, 8-9, 609-618.
52. Pinho, S. S., Oliveira, P., Cabral, J., Carvalho, S. et al., Loss and recovery of Mgat3 and GnT-III mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. PLoS ONE 2012, 7, 33191.
53. Barthel, S. R., Wiese, G. K., Cho, J., Opperman, M. J. et al., Alpha 1, 3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc. Natl. Acad. Sci. USA 2009, 106, 19491-19496.
54. Culig, Z., Hittmair, A., Hobisch, A., Bartsch, G. et al., Expression of lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma. Prostate, 1998, 36, 162-167.
55. Jorgensen, T., Berner, A., Kaalhus, O., Tveter, K. J. et al., Up-regulation of the oligosaccharide sialyl Lewis X: a new prognostic parameter in metastatic prostate cancer. Cancer Res. 1995, 55, 1817-1819.
56. Martensson, S., Bigler, S. A., Brown, M., Lange, P. H. et al., Sialyl-Lewis (x) and related carbohydrate antigens in the prostate. Hum. Pathol. 1995, 26, 735-739.
57. Barthel, S. R., Gavino, J. D., Wiese, G. K., Jaynes, J. M. et al., Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology 2008, 18, 806-817.